• Vivos Therapeutics agreed to acquire an 11% fully diluted stake in SOD Sciences and 50% co-ownership of its proprietary pseudohypoxia test.
• Consideration comprises 12,000 shares of Series C Convertible Preferred Stock with a $12 million aggregate stated value; no cash is payable.
• Preferred shares convert at $0.15 into up to 80 million common shares, subject to a 19.99% exchange cap pending stockholder approval.
• Closing is expected on or about October 15, 2026, subject to customary conditions.
• The transaction could increase reported stockholders' equity, supporting efforts to regain compliance with Nasdaq's minimum equity requirement, subject to accounting review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610150845PRIMZONEFULLFEED9846289) on October 15, 2026, and is solely responsible for the information contained therein.